Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction, gastric, head and neck, non-small cell lung and bladder cancers Tumor shrinkage observed in 56% of evaluable patients, with an 18% objective response rate...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


